Published in Front Oncol on March 09, 2016
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases | NCT02085070
SRS (Stereotactic Radiosurgery) Plus Ipilimumab | NCT01950195
Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases (ABC) | NCT02374242
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. Oncologist (2016) 0.75
Immune checkpoint inhibitors in challenging populations. Cancer (2017) 0.75
Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. Transl Lung Cancer Res (2016) 0.75
Radiotherapy for cranial and brain metastases from prostate cancer: a systematic review. J Neurooncol (2017) 0.75
Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options. Cell Oncol (Dordr) (2017) 0.75
Survival patterns of 5750 SRS-treated brain metastasis patients as a function of the number of lesions. World Neurosurg (2017) 0.75
Special topics in immunotherapy and radiation therapy: reirradiation and palliation. Transl Lung Cancer Res (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 7.49
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol (2015) 6.07
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol (2004) 3.97
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50
Trastuzumab in CSF. J Clin Oncol (2000) 2.35
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 2.28
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg (2012) 2.28
Trafficking of immune cells in the central nervous system. J Clin Invest (2010) 2.17
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 2.03
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res (2007) 1.86
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol (2009) 1.39
Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer (2010) 1.37
Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res (2011) 1.35
Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS (2011) 1.21
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys (2015) 1.21
Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol (2013) 1.15
Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother (2002) 1.15
Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med (2013) 1.15
Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother (2013) 1.13
Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res (2013) 1.08
Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol (2010) 1.04
Gamma Knife surgery for the treatment of melanoma metastases: the effect of intratumoral hemorrhage on survival. J Neurosurg (2008) 1.04
Stereotactic laser induced thermotherapy (LITT): a novel treatment for brain lesions regrowing after radiosurgery. J Neurooncol (2013) 1.00
Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol (2015) 0.92
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol (2014) 0.91
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res (2015) 0.90
Melanoma brain metastases: is it time to reassess the bias? Curr Probl Cancer (2011) 0.90
The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients. Am J Clin Oncol (2013) 0.88
Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg (2015) 0.88
Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res (1982) 0.87
Human central nervous system and plasma pharmacology of mitoxantrone. J Neurooncol (1988) 0.85
Concentration of vinblastine in human intracerebral tumor and other tissues. J Neurooncol (1983) 0.84
Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neurooncol (1984) 0.84
Gamma knife radiosurgery for malignant melanoma brain metastases. Clin Neurosurg (2007) 0.83
Bevacizumab as front-line treatment of brain metastases from solid tumors: a case series. Anticancer Res (2013) 0.82
Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer. EJNMMI Res (2015) 0.82
Clinical trials in melanoma patients with brain metastases. Pigment Cell Melanoma Res (2015) 0.78
Immune checkpoint blockade in patients with melanoma metastatic to the brain. Semin Oncol (2015) 0.78
Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results. Chemotherapy (2015) 0.77
Afatinib for Erlotinib Refractory Brain Metastases in a Patient with EGFR-Mutant Non-Small-Cell Lung Cancer: Can High-Affinity TKI Substitute for High-Dose TKI? J Thorac Oncol (2015) 0.77
Bevacizumab as first-line therapy for patients with brain metastases from renal carcinoma: a case series. Clin Genitourin Cancer (2014) 0.76